Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
Benzinga (Thu, 28-Mar 12:39 PM ET)
Gilead gains label extension for hepatitis B drug Vemlidy
Seeking Alpha News (Thu, 28-Mar 11:04 AM ET)
Business Wire (Thu, 28-Mar 8:30 AM ET)
Xilio stock jumps on Gilead Sciences license deal
Seeking Alpha News (Thu, 28-Mar 8:23 AM ET)
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Globe Newswire (Thu, 28-Mar 7:00 AM ET)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga (Wed, 27-Mar 8:13 AM ET)
TipRanks (Sun, 24-Mar 5:03 AM ET)
Gilead Sciences Announces Completion of Acquisition of CymaBay
Business Wire (Fri, 22-Mar 9:18 AM ET)
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
Business Wire (Mon, 18-Mar 7:29 PM ET)
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
Business Wire (Mon, 11-Mar 8:24 AM ET)
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Gilead Sciences trades on the NASDAQ stock market under the symbol GILD.
As of March 28, 2024, GILD stock price climbed to $73.46 with 2,157,474 million shares trading.
GILD has a beta of 0.49, meaning it tends to be less sensitive to market movements. GILD has a correlation of 0.06 to the broad based SPY ETF.
GILD has a market cap of $91.53 billion. This is considered a Large Cap stock.
Last quarter Gilead Sciences reported $7 billion in Revenue and $1.72 earnings per share. This beat revenue expectation by $25 million and missed earnings estimates by -$.06.
In the last 3 years, GILD stock traded as high as $89.74 and as low as $57.17.
The top ETF exchange traded funds that GILD belongs to (by Net Assets): VTI, VOO, QQQ, SPY, IVV.
GILD has underperformed the market in the last year with a price return of -3.9% while the SPY ETF gained +33.6%. GILD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.6% and -1.3%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
GILD support price is $72.35 and resistance is $73.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GILD stock will trade within this expected range on the day.